Reported 4 days ago
Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) experienced a dramatic 35.8% rise in stock price last week, closing at $27.72, following the FDA's decision to replace animal testing with AI methods in drug development. This news boosted investor confidence, particularly for biotech companies utilizing AI in their processes, as it is expected to enhance drug safety, reduce development costs, and improve overall efficiency in drug evaluation.
Source: YAHOO